All ‘Adverse Events Following Immunisation’ (AEFI) after COVID-19 vaccinations continue to be monitored, a senior Union Health Ministry official, who did not wish to be named, said on Thursday.
Earlier this week, the pharmaceutical company AstraZeneca has admitted in a U.K. court that its COVID-19 vaccine had the potential to cause thrombosis with thrombocytopenia syndrome (TTS), a rare side effect associated with blood clotting.
“After 2022-23, the demand for COVID vaccine dropped and now we are seeing less than a lakh people coming in for vaccination or the booster dose. In India, all vaccine-related AEFI are routinely monitored and COVID is no exception,” N.K. Arora, who has been a part of the National Technical Advisory Group on Immunisation (NTAGI), said.
